April 2025 PureTech Health plc PureTech Announces Annual Results for Year Ended

PureTech Announces Annual Results for Year Ended December 31, 2024

Innovation engine drives meaningful clinical, regulatory, and financial milestones, including positive Phase 2b results for wholly-owned

deupirfenidone (LYT-100) in IPF, compelling Phase 1b data for wholly-owned LYT-200 in AML and solid tumors, FDA approval of PureTech-invented Cobenfy 1 for schizophrenia, and rapid growth of Founded Entity2, Seaport Therapeutics, which

raised over $325 million

Capital-efficient operations support robust balance sheet with PureTech level cash, cash equivalents,

and short-term investments of $366.8 million3 and consolidated cash, cash equivalents, and short-term investments of $367.3 million4 as of

December 31, 2024, with operational runway into at least 2027

As of March 31, 2025, PureTech level cash, cash

equivalents and short-term investments were $339.1 million5

webcast and conference call today at 9:00am EDT / 2:00pm BST

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ( PureTech or the

Company ) today announces its results for the year ended December 31, 2024, as well as its cash balance as of the first quarter ended March 31, 2025. The following information represents select highlights from the full UK Annual

Report and Accounts, except as noted herein, a portion of which will be filed as an exhibit to PureTech s Annual Report on Form 20-F for the fiscal year ended December 31, 2024, to be filed with the

United States Securities and Exchange Commission (the SEC ) and will also be available later today at https://investors.puretechhealth.com/financials-filings/reports.

Webcast and conference call details

PureTech management team will host a conference call at 9:00am EDT / 2:00pm BST today, April 30, 2025, to discuss these results. A live webcast and presentation slides will be available on the investors section of PureTech s website under

the Events and Presentations tab. To join by phone, please dial:

United Kingdom (Local): +44 20 3936 2999

United States (Local): +1 646 233 4753

Global Dial-In Numbers

For those unable to listen to the call live, a replay will be available on the PureTech website.

Commenting on the annual results, Bharatt Chowrira, Ph.D., J.D., Chief Executive Officer of PureTech, said:

2024 was a defining year for PureTech. Our unique hub-and-spoke model

delivered transformative progress across our Wholly-Owned6 and Founded Entity programs, advancing our mission and generating meaningful value for patients and shareholders.

The FDA approval of Cobenfy (formerly KarXT) the first new mechanism for schizophrenia

in over 50 years was a milestone, not only for the field, but for PureTech. Invented by our team and advanced by Karuna Therapeutics, now part of Bristol Myers Squibb (BMS), the program exemplifies our ability to translate bold scientific ideas

into impactful therapies. With approximately $1.1 billion in cash generated from an initial $18.5 million investment, it also demonstrates the financial strength of our model.

That strength was further validated by the positive results from our Phase 2b trial of our

wholly-owned deupirfenidone (LYT-100), which showed the potential to stabilize lung function decline over 26 weeks in patients with idiopathic pulmonary fibrosis (IPF) a result that, to our knowledge, has

not been demonstrated with any other investigational therapy in IPF to date. Based on these data, we believe that deupirfenidone has the potential to become a new

standard-of-care treatment for this debilitating rare disease and to help many patients who currently remain untreated. We are targeting a meeting with the FDA before

the end of the third quarter, with the goal of initiating a Phase 3 trial by the end of the year. Subject to feedback from the FDA with respect to trial design, we don t believe our current cash balance would be sufficient to fully fund a Phase

3 trial. As such, we are focused on identifying external sources of capital to advance this program and unlock the full potential of this promising therapy.

We also advanced LYT-200 through our Founded Entity, Gallop Oncology, where it is emerging as a promising

candidate for the treatment of both hematological malignancies and solid tumors. In the ongoing acute myeloid leukemia (AML) trial, LYT-200 has demonstrated clinical activity and disease stabilization in

heavily pretreated patients, both as a monotherapy and in combination with standard-of-care therapy. In the recently completed head and neck cancer trial, topline data

with LYT-200 shared for the first time today demonstrate a favorable safety profile, disease control, and early signs of efficacy.

We also launched Seaport Therapeutics, which raised over $325 million in two oversubscribed financings to advance neuropsychiatric candidates that

were identified at PureTech based on our Glyph platform. This momentum underscores the durability and scalability of our innovation engine, which has produced 29 therapeutic candidates to date three of which have achieved FDA approval.

As we look ahead, our focus remains clear: to execute with discipline, continue to harness our highly productive innovation R&D engine with high

capital efficiency, maintain a strong balance sheet, and unlock the full potential of our programs to drive long-term patient impact and shareholder value. We are proud of what we achieved in 2024 and we are energized by the opportunities that

2024 and Early 2025 Operational Highlights

For full details, please see PureTech s 2024 Annual Report.

Delivered clinical, regulatory, and financial milestones across our Wholly-Owned Programs and Founded Entities, reinforcing the strength of our innovative

R&D engine and its potential to drive long-term value for patients and shareholders. Key highlights include the following:

Financial Highlights

PureTech Health will release its Annual Report for the year ended December 31, 2024, today. In compliance with the Financial Conduct Authority s

Listing Rule 9.6.3, the following documents will be submitted to the National Storage Mechanism today and be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

Printed copies of these documents together with the Form of Proxy will be posted to shareholders in accordance with applicable UK rules. The Company will

provide a hard copy of the Annual Report containing its audited financial statements, free of charge, to its shareholders upon request in accordance with Nasdaq requirements. Requests should be directed in writing by email to ir@puretechhealth.com.

Copies will also be available electronically on the Investor Relations section of the Company s website at https://investors.puretechhealth.com/financials-filings/reports.

PureTech s 2025 AGM will be held on June 16, 2025, at 11:00am EDT /4:00pm BST at the Company s Corporate Headquarters at 6 Tide Street, Suite

400, Boston, Massachusetts, United States.

Shareholders are strongly encouraged to submit a proxy vote in advance of the meeting and to appoint the Chair

of the meeting to act as their proxy. If a shareholder wishes to attend the meeting in person, we ask that the shareholder notify the Company by email to ir@puretechhealth.com to assist us in planning and implementing arrangements for this

Any specific questions on the business of the AGM and resolutions can be submitted ahead of the meeting by e-mail to ir@puretechhealth.com (marked for the attention of Mr. Charles Sherwood).

encouraged to complete and return their votes by proxy, and to do so no later than 4:00pm BST on June 12, 2025. This will appoint the chair of the meeting as proxy and will ensure that votes will be counted even though attendance at the meeting

is restricted and you are unable to attend in person. Details of how to appoint a proxy are set out in the notice of AGM.

PureTech will keep shareholders

updated of any changes it may decide to make to the current plans for the AGM. Please visit the Company s website at www.puretechhealth.com for the most up to date information.

About PureTech Health

clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep portfolio through its experienced research and development

team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech s R&D

engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these

programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration-enabling studies. All of the underlying programs and platforms that resulted in this

portfolio of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

For more information, visit www.puretechhealth.com or connect with us on X (formerly Twitter) @puretechh.

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of

1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those statements that relate to expectations regarding

PureTech s and its Founded Entities future prospects, development plans and strategies, including the success and scalability of the Company s R&D model, the progress and timing of clinical trials and data readouts, the timing of

potential regulatory submissions, and the sufficiency of available resources and expected operational runway. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other

important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, the following: our history of incurring significant operating losses since our inception;

our ability to realize value from our Founded Entities; our need for additional funding to achieve our business goals, which may not be available and which may force us to delay, limit or terminate certain of our therapeutic development efforts; our

limited information about and limited control or influence over our Non-Controlled Founded Entities; the lengthy and expensive process of preclinical and clinical drug development, which has an uncertain

outcome and potential for substantial delays; potential difficulties with enrolling patients in clinical trials, which could delay our clinical development activities; side effects, adverse events or other safety risks which could be associated with

our therapeutic candidates and delay or halt their clinical development; our ability to obtain regulatory approval for and commercialize our therapeutic candidates; our ability to compete with companies currently marketing or engaged in the

development of treatments for indications within our programs are designed to target; our ability to realize the benefits of our collaborations, licenses and other arrangements; the impact of government laws and regulations; our ability to maintain

and protect our intellectual property rights; our reliance on third parties, including clinical research organizations, clinical investigators and manufacturers; our vulnerability to natural disasters, global economic factors, geo-political actions and unexpected events; and those additional important factors described under the caption Risk Factors in our Annual Report on Form 20-F for

the year ended December 31, 2024, to be filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in

which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking

statements, whether as a result of new information, future events or otherwise.

Letter from the Chair

A Year of Successes for PureTech Innovation

highlight the power of our proven hub-and-spoke model to advance science, build value, and deliver meaningful outcomes.

2024 was a landmark year for PureTech one defined by breakthrough achievements that created long-term value for both patients and shareholders.

These accomplishments reflect not only the power of our innovation engine but also the dedication, discipline, and excellence of the PureTech team. From bold scientific bets to smart capital decisions, this year demonstrated what s possible

when vision meets execution.

We reached major milestones throughout the year, including the third FDA approval for a therapeutic invented at PureTech,

transformative financings for Seaport Therapeutics (a PureTech Founded Entity), and unprecedented clinical results for deupirfenidone (LYT-100), an asset fully owned by PureTech. These achievements, supported

by a strong year-end balance sheet of $367 million1, underscore the strength of our capital-efficient and disciplined approach.

A standout achievement was the U.S. FDA approval of KarXT now marketed by Bristol Myers Squibb (BMS) as Cobenfy for the treatment of schizophrenia in adults. Invented and initially developed at PureTech, Cobenfy represents the first drug with a novel mechanism of action for schizophrenia in over 50

years, underscoring our scientific invention and leadership. Complementing this historic approval was a major financial milestone: the acquisition of Karuna Therapeutics, our Founded Entity that shepherded Cobenfy through late-stage development, by

BMS for $14 billion. Through the monetization of our equity holdings including proceeds from the BMS acquisition and a strategic royalty agreement PureTech has generated approximately $1.1 billion in cash from the

$18.5 million it initially invested in the program. Together, these achievements highlight the power of our proven hub-and-spoke model (see page 10 of our Annual

Report) to advance science, build value, and deliver meaningful outcomes.

Expanding on this success, we launched Seaport Therapeutics our latest

Founded Entity. Seaport builds on our leadership in neuroscience, a field where we reignited broader investment interest through the success of Karuna. Several key team members from Karuna are now involved at Seaport, leveraging their expertise to

advance a promising pipeline of neuropsychiatric medicines. With over $325 million raised across two oversubscribed Series A and Series B financings, Seaport is now advancing multiple drugs developed at PureTech using the Glyph platform that